Episode Details
Back to Episodes352. Chris Kiple, CEO of Solius Labs
Description
Today, I'm joined by Chris Kiple, CEO of Solius Labs.
A decade in development, Solius's FDA-cleared UVB light therapy device personalizes dosage by skin type, aiming to replicate the benefits of sunlight while minimizing carcinogenic risk.
In this episode, we discuss sunlight as a foundational pillar of health and longevity.
We also cover:
- Why sun avoidance is deadlier than smoking
- Designing a skin scanner for personalized UVB dosing
- Moving UVB therapy from clinical dermatology to consumer health
Subscribe to the podcast → insider.fitt.co/podcast
Subscribe to our newsletter → insider.fitt.co/subscribe
Follow us on LinkedIn → linkedin.com/company/fittinsider
Website: www.solius.com
Instagram: https://www.instagram.com/soliuslabs
-
The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities.
Fitt Talent: https://talent.fitt.co/
Consulting: https://consulting.fitt.co/
Investments: https://capital.fitt.co/
Chapters:
(00:00) Introduction
(00:29) Swedish longevity study
(01:20) Chris background and Solius overview
(02:05) UVB light therapy foundation
(04:00) 10-year development and timing
(05:07) Sun exposure evolution and skin type
(08:10) Solius technology and personalized dosing
(09:35) Skin scanning and dosing mechanism
(11:00) FDA clearance and safety focus
(12:40) OTC vs. prescription positioning
(14:15) Safety risk contextualization
(15:42) Healthcare partnerships strategy
(17:50) Dermatology focus
(19:00) Orthopedic and cardiovascular applications
(20:32) Longevity clinic partnerships
(22:35) Swedish and UK biobank studies
(26:00) Hormone production benefits
(27:20) Cardiovascular and nitric oxide improvements
(28:30) Microbiome diversity impact
(31:15) Platform evolution and future devices
(33:20) Team-building and advisory board
(34:45) Listening to early users
(36:40) Where to find
(38:07) Conclusion